Mallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
UPDATE: Mallinckrodt plc (MNK) PT Lowered to $18 at Goldman Sachs
May 10, 2018 8:02 AM EDT(Updated - May 10, 2018 8:03 AM EDT)
(updated to correct price target)
Goldman Sachs lowered its price target on Mallinckrodt plc (NYSE: MNK) to $18.00 (from $21.00) while maintaining a Neutral rating.
... MoreCantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1Q
May 9, 2018 7:56 AM EDTCantor Fitzgerald reiterated an Overweight rating and $42.00 price target on Mallinckrodt plc (NYSE: MNK) following the company's 1Q earnings report. MNK reported EPS of $1.31, $0.23 above FactSet consensus. MNK did not change its 2018 EPS guidance of $6.00-6.50 (FactSet consensus was $6.17).
Analyst Louise Chen believes that... More
Mallinckrodt plc (MNK) PT Lowered to $29 at BMO Capital
May 9, 2018 7:47 AM EDTBMO Capital lowered its price target on Mallinckrodt plc (NYSE: MNK) to $29.00 (from $33.00) while maintaining a Outperform rating.
Analyst Gary Nachman commented, "MNK delivered good results in 1Q, particularly relative to lowered expectations for Acthar. Management indicated it is making headway stabilizing that... More
Mallinckrodt (MNK) Provides Facts on H.P. Acthar Gel in Resonse to CBS' 60 Minutes
May 7, 2018 7:01 AM EDTMallinckrodt Pharmaceuticals (NYSE: MNK), in response to a segment aired on CBS' 60 Minutes on Sunday, May 6, has posted facts related to H.P. Acthar® Gel (repository corticotropin injection) on its website at www.mallinckrodt.com/acthar.
... MoreMallinckrodt (MNK) Seen as Target of Negative Upcoming 60 Minutes Episode
May 4, 2018 10:06 AM EDTMallinckrodt (NYSE: MNK) is seen as the target of an upcoming 60 Minutes episode.
"THE ROCKFORD FILE A look at the fight that Rockford, Ill., took up against the high cost of prescription drugs explains why they cost more in the U.S.... More
Mallinckrodt (MNK) Reports Negative FDA Advisory Committee Vote on Stannsoporfin for Treatment of Newborns at Risk of Developing Severe Jaundice
May 4, 2018 6:21 AM EDTMallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today expressed disappointment that, in a joint meeting, the U.S. Food and Drug Administration's (FDA's) Gastrointestinal Drugs Advisory Committee... More
